Zentalis Pharmaceuticals provided a corporate update highlighting 2025 progress and outlining key 2026 milestones for its azenosertib program in Cyclin E1-positive platinum-resistant ovarian cancer. In 2025, the company completed enrollment in Part 2a of its Phase 2 DENALI trial to confirm the dose for registration-intended studies, aligned with the U.S. Food and Drug Administration on the design of ASPENOVA, a randomized Phase 3 confirmatory trial versus standard chemotherapy in Cyclin E1-positive PROC, and reported strong data across three PROC studies, including clinically meaningful efficacy and a manageable safety profile at 400 mg once daily on a 5:2 schedule. Zentalis also reported holding $280.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, which it expects to fund operations into late 2027 following a pipeline-focused restructuring, and it set 2026 targets that include DENALI Part 2a dose confirmation and ASPENOVA trial initiation in the first half of the year, as well as a DENALI Part 2 topline readout by year-end 2026 that could be pivotal for the company’s regulatory path and competitive positioning in ovarian cancer therapeutics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.